Immunotherapy in relapsed refractory Hodgkin lymphoma
A chromosomal alteration present in almost all patients with Hodgkin lymphoma makes the disease uniquely vulnerable to PD-1/PD-L1 immune checkpoint blockers. Astrid Pavlovsky reviews the trial evidence and clinical experience, and looks to the future [more]